Cytori Therapeutics, Inc. received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application that protects key therapeutic methods for its breast and soft tissue reconstruction products. This patent will protect Cytori's existing and future products when sold in the U.S.
Cytori currently sells the Celution 800/CRS System, which creates adipose tissue derived stem and regenerative cell enhanced autologous fat grafts, in many countries around the world. The allowed patent will protect alternative configurations of the Celution 800/CRS System, including smaller versions with accelerated processing times tailored to procedures such as the treatment of stress urinary incontinence.
This patent allowance expands on the Company's previously issued core device patent, U.S. Patent No. 7,390,484, as well as the Company's previously issued U.S. Patent No. 7,429,488 relating to automated methods of creating cell enhanced fat grafts.
Cytori's intellectual property portfolio related to the devices, methods and uses of adipose-derived stem and regenerative cells includes ten U.S. and International patents and numerous applications worldwide.